Can you be born with gynaecomastia? Yes — breast tissue enlargement in newborns is a well-recognised physiological finding, affecting both male and female infants. Known more precisely as neonatal breast enlargement, it occurs due to exposure to high levels of maternal oestrogens during pregnancy, which cross the placenta and stimulate breast tissue development in the unborn child. Assessed as part of the NHS Newborn and Infant Physical Examination (NIPE), this condition is considered normal in the vast majority of cases and resolves without treatment. This article explains the causes, assessment, when to seek advice, and the outlook for affected infants.

Neonatal Breast Enlargement at Birth: What the Evidence Shows

Neonatal breast enlargement is a common physiological finding caused by maternal oestrogens crossing the placenta; it affects both sexes and is recognised by the NHS as normal in the vast majority of newborns.

Yes, it is entirely possible to be born with enlarged or palpable breast tissue, or to develop it within the first days or weeks of life. Neonatal breast enlargement — sometimes referred to as neonatal gynaecomastia in older texts — is a well-recognised and relatively common physiological finding. Studies suggest that a substantial proportion of newborns may exhibit some degree of breast tissue enlargement at birth or shortly thereafter, affecting both male and female infants.

It is worth noting that the term 'gynaecomastia' is more precisely applied to glandular breast tissue enlargement in males beyond infancy; in newborns of either sex, 'neonatal breast enlargement' or 'neonatal breast hypertrophy' is the more accurate description. The NHS acknowledges this as a normal physiological finding in newborns, and it is assessed as part of the routine Newborn and Infant Physical Examination (NIPE).

The condition arises primarily due to hormonal influences during pregnancy. Throughout gestation, the foetus is exposed to high circulating levels of maternal oestrogens, which cross the placenta and stimulate breast tissue development in the unborn child. This is a normal part of foetal development and does not indicate an underlying pathology in the vast majority of cases.

It is important to distinguish between physiological neonatal breast enlargement — which resolves naturally — and rarer forms linked to underlying genetic or endocrine conditions. While most cases require no intervention, a small number may warrant further investigation, particularly if the breast enlargement is asymmetrical, associated with other physical findings, or fails to resolve within the expected timeframe. Understanding the evidence behind this condition helps parents and clinicians respond appropriately without unnecessary alarm.

Common Causes of Breast Enlargement in Newborns and Infants

The most common cause is transplacental maternal oestrogen transfer, with a secondary contribution from the 'mini-puberty of infancy'; underlying pathology is identified in only a small minority of cases.

The most common cause of breast enlargement in newborns is transplacental maternal oestrogen transfer. During pregnancy, the placenta produces significant quantities of oestrogens, and these hormones freely cross into the foetal circulation. In the final weeks of pregnancy, foetal oestrogen levels can be particularly elevated, stimulating glandular breast tissue in both male and female neonates. Once the baby is born and separated from the maternal hormonal environment, oestrogen levels gradually decline, and the breast tissue typically regresses on its own.

A further recognised contributor is the 'mini-puberty' of infancy — a transient, physiological activation of the hypothalamic–pituitary–gonadal (HPG) axis that occurs in the first few months of life. This brief hormonal surge can maintain or mildly prolong breast tissue in some infants before naturally subsiding.

Some sources have suggested that breast milk ingestion may play a minor role, as human breast milk contains small quantities of oestrogens. However, the evidence for this as a clinically significant cause of prolonged breast enlargement is not well established. Parents should be reassured that breastfeeding should continue and is not a reason for concern in this context.

Less commonly, neonatal breast enlargement may be associated with:

• Exogenous hormone exposure — including certain topical products or medications used by the mother during pregnancy or applied to the infant; this is rare but worth considering if other causes are excluded

• Rare oestrogen-secreting tumours — extraordinarily uncommon in neonates, but relevant if other clinical features are present

It should be noted that conditions such as Klinefelter syndrome (47,XXY) and congenital adrenal hyperplasia (CAH) are not recognised typical causes of breast enlargement in the neonatal period. Klinefelter syndrome is associated with gynaecomastia in adolescence and adulthood, while CAH primarily presents with androgen excess rather than oestrogen-driven breast tissue changes. These conditions may be identified incidentally during investigation of atypical presentations, but they should not be listed as routine neonatal causes.

In the majority of cases, no underlying pathology is identified, and the breast enlargement is classified as physiological. A thorough clinical assessment remains important to rule out the less common but clinically significant causes outlined above.

How Neonatal Breast Enlargement Is Assessed

Assessment is clinical, based on history and physical examination; bilateral symmetrical enlargement with no other abnormal findings requires no investigations, while atypical features may prompt hormone tests, karyotyping, or specialist referral.

Assessment of breast enlargement in a newborn typically begins with a detailed clinical history and physical examination. The clinician will review the maternal pregnancy history, including any medications, hormonal treatments, or supplements taken during pregnancy, as well as the infant's gestational age, birth weight, and any associated physical findings.

During the physical examination, the clinician will assess:

• The size and consistency of the breast tissue — true glandular tissue feels firm and disc-like beneath the nipple, distinct from fatty tissue

• Symmetry — bilateral enlargement is more commonly physiological, whereas unilateral or markedly asymmetrical findings may warrant further investigation

• Associated features — such as unusual genital development, abnormal pigmentation, or signs of systemic illness, which may suggest an underlying condition

In straightforward cases of bilateral, symmetrical neonatal breast enlargement with no other abnormal findings, no investigations are routinely required. The diagnosis is clinical, and watchful waiting is the standard approach. This is consistent with the NIPE Programme Handbook (UKHSA), which supports clinical assessment and reassurance in typical presentations.

However, if there are concerns about an underlying condition, investigations may include:

• Serum hormone levels — including oestradiol, testosterone, LH, FSH, and DHEAS, guided by clinical suspicion

• Chromosomal karyotyping — if a chromosomal abnormality is suspected on clinical grounds

• Adrenal function tests — only if clinical features specifically suggest an adrenal disorder

• Ultrasound imaging — primarily indicated if mastitis or a breast abscess is suspected; adrenal or gonadal imaging is reserved for cases directed by specific clinical findings

Referral to a paediatric endocrinologist may be appropriate where investigations reveal hormonal imbalances or where a genetic condition is suspected. UK paediatric endocrine referral pathways, including those supported by the British Society for Paediatric Endocrinology and Diabetes (BSPED), provide guidance on when specialist involvement is warranted in complex or atypical presentations.

When to Seek Medical Advice for a Newborn With Breast Tissue

Seek medical advice if breast tissue is growing, asymmetrical, red, tender, or associated with unusual genital development; a fever of 38°C or above in an infant under 3 months always requires urgent same-day assessment.

For most parents, discovering that their newborn has palpable breast tissue can be understandably concerning. It is reassuring to know that, in the majority of cases, this is a normal physiological finding that resolves without treatment. However, there are specific circumstances in which it is important to seek prompt medical advice.

Contact your GP, midwife, or health visitor if you notice:

• Breast tissue that appears to be growing rather than reducing after the first few weeks of life

• Redness, warmth, or tenderness around the breast area, which may indicate mastitis or a breast abscess — a rare but treatable condition in neonates

• Nipple discharge that is blood-stained, purulent, or otherwise unusual; a small amount of milky secretion (sometimes called 'witch's milk') can occur transiently in newborns and is normal

• Asymmetrical or rapidly enlarging breast tissue on one side only

• Any associated features such as unusual genital development, poor weight gain, or signs of hormonal disturbance

• Avoid squeezing or manipulating the breast tissue, as this can introduce infection

Seek urgent same-day medical assessment (contact your GP urgently, call NHS 111, or attend A&E if your baby appears seriously unwell) if your baby develops a fever of 38°C or above and is under 3 months of age. A high temperature in a very young infant always requires prompt clinical review, regardless of the apparent cause.

Neonatal breast tissue is also assessed as part of the routine NIPE (Newborn and Infant Physical Examination), offered to all babies in England within 72 hours of birth and again at 6–8 weeks. This structured check provides an opportunity for a trained clinician to assess the finding in context and advise accordingly.

Parents should feel empowered to raise any concerns with their health visitor, GP, or paediatrician. Early discussion can prevent unnecessary anxiety and ensure that the small number of cases requiring further investigation are identified promptly.

Treatment and Outlook for Breast Enlargement Present From Birth

No treatment is required for physiological neonatal breast enlargement, which resolves spontaneously in most infants by six months; surgical intervention is not appropriate at this age.

The outlook for neonatal breast enlargement is, in the vast majority of cases, excellent. Physiological breast tissue enlargement in newborns typically resolves spontaneously within a few weeks to months — most commonly by around six months of age, though in some infants it may persist for up to twelve months before resolving fully. No specific treatment is required during this period.

Parents are advised to avoid squeezing or manipulating the breast tissue, as this can introduce infection and may cause unnecessary discomfort to the infant.

Where an underlying cause has been identified, management is directed at the root condition rather than the breast enlargement itself. For example, if exogenous hormone exposure is identified as a contributing factor, removing the source — such as discontinuing a particular topical product — is usually sufficient. Any further management of rare underlying conditions would be guided by specialist paediatric or endocrine teams on an individual basis.

Surgical intervention is not appropriate for neonatal breast enlargement. In older children and adolescents, any consideration of surgery for persistent, symptomatic gynaecomastia would be an individualised decision made by specialist teams, taking into account the clinical picture, impact on quality of life, and response to other measures. Such decisions are not made routinely and would always involve specialist input.

In summary, breast enlargement present from birth is a recognised, largely benign phenomenon rooted in normal hormonal physiology. With appropriate monitoring and, where necessary, specialist input, the condition carries a very favourable prognosis. Parents and carers can be reassured that, with the right guidance, the vast majority of affected infants will experience complete resolution without any lasting effects.

Frequently Asked Questions